United we stand: Double targeting of CD79B and CD20 in diffuse large B‐cell lymphoma

Polatuzumab vedotin is antibody‐drug conjugate (ADC) targeting CD79B approved for the treatment of patients with relapsed/refractory diffuse large B‐cell lymphoma when given in combination with bendamustine and rituximab. The report by Kawasaki et al. provide hints on what might be happening in lymp...

Descripción completa

Detalles Bibliográficos
Autores principales: Tarantelli, Chiara, Bertoni, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804191/
https://www.ncbi.nlm.nih.gov/pubmed/35917107
http://dx.doi.org/10.1111/bjh.18384
Descripción
Sumario:Polatuzumab vedotin is antibody‐drug conjugate (ADC) targeting CD79B approved for the treatment of patients with relapsed/refractory diffuse large B‐cell lymphoma when given in combination with bendamustine and rituximab. The report by Kawasaki et al. provide hints on what might be happening in lymphoma cells exposed to polatuzumab vedotin and to rituximab and on potential mechanism of resistance to the ADC. Commentary on: Kawasaki et al. The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B‐cell lymphoma. Br J Haematol 2022;199:245‐255.

Ejemplares similares